Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Glaukos Corporation
< Previous
1
2
Next >
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 28, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in the Stephens Annual Investment Conference
November 07, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Corporation Announces Third Quarter 2022 Financial Results
November 02, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
October 12, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
September 28, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
September 07, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
September 06, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
August 24, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
August 03, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Corporation Announces Second Quarter 2022 Financial Results
August 03, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
July 13, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in the William Blair Growth Stock Conference
June 02, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
May 20, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Corporation Announces First Quarter 2022 Financial Results
May 04, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
April 21, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces the Release of its 2021 Sustainability Report
April 20, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
April 13, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
March 14, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Executive Leadership Changes
February 07, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
February 01, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
January 11, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
January 11, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
January 11, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces FDA 510(k) Clearance of iPRIME™
January 06, 2022
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 29, 2021
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
December 20, 2021
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Announces Participation in Upcoming Investor Conferences
November 19, 2021
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
November 11, 2021
From
Glaukos Corporation
Via
Business Wire
Tickers
GKOS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.